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Background and aim: This study aimed to determine the frequency of relapse, the risk factors for relapse, and the correlation of relapse
with immunosuppressive regimens in patients with granulomatosis polyangiitis (GPA).
Materials and methods: The demographic characteristics, the clinical, laboratory, and radiological findings, the immunosuppressive
treatment regimens, and the remission and relapse rates of 50 patients with GPA were obtained retrospectively from medical records.
Results: The mean relapse-free survival rates at years 1, 3, and 5 were 82%, 60%, and 50%, respectively. Increased relapse rates were
observed in patients who had cavitary lung lesions (52.2% vs. 22.2%, p = 0.04) and in those who had elevated serum creatinine levels
(1.8 vs. 0.9, p = 0.00). The patients received two different types of remission induction therapies; 36% of them received the combination
therapy involving cyclophosphamide (CYC) and rituximab (RTX), and 62% received CYC alone. Relapse was observed in 22.3% of the
patients who received the combination remission induction therapy and in 61.3% of the patients who received CYC alone (P = 0.003).
Conclusion: An increased risk of relapse was observed in patients who had cavitary lung lesions and in those who had elevated serum
creatinine levels. The combined use of RTX and CYC for the remission therapy in GPA reduced the relapse rates compared with the use
of CYC alone.
Key words: Granulomatous polyangiitis, relapse, vasculitis

1. Introduction
Granulomatosis polyangiitis (GPA) is a form of necrotizing
granulomatous vasculitis associated with antineutrophil
cytoplasmic antibodies (ANCA), and it affects smalland medium sized blood vessels [1]. GPA is diagnosed
based on clinical, serological (ANCA positivity), and
histopathological findings. While GPA affects a wide
array of organs, it is most frequently encountered in the
respiratory tract and in the kidneys [1]. GPA is a severe
condition that can manifest as rapid organ damage and
can lead to death if left untreated. The 5-year survival rate
for GPA has risen by up to 70%–78% as a result of the use
of novel immunosuppressants and biologic agents [2,3],
and its 5-year relapse rate is approximately 40%–50% [1,4].
The primary goal of GPA treatment is to achieve
remission, and the secondary goal is to prevent relapse
(maintenance) [5]. Relapse in GPA is especially concerning
due to aggravated organ damage that can be life-threatening.
To avoid relapse, clinicians prefer administering intensive
and long-term immunosuppressive treatments. While

these treatments prevent relapse in half of GPA patients,
the long-term use of immunosuppressants at high doses
involves other risks secondary to their cumulative
side effects (e.g., secondary malignancy, infection, and
increased mortality) [5]. Yet, a consensus on how to reduce
relapse and when to stop immunosuppressive therapy in
patients with GPA remains nonexistent. Thus, this study
aimed to determine the frequency and risk factors of
relapse in GPA patients.
2. Materials and methods
2.1. Participants
This study was approved by the Başkent University
Institutional Review Board (project no.: KA19/287)
and was supported by the Başkent University Research
Fund. Fifty adult patients who were diagnosed with GPA
and were treated at the Rheumatology Department of
Başkent University Adana Dr Turgut Noyan Research and
Medical Hospital between January 2005 and August 2019
were included in this study. GPA diagnosis was based on
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the American College of Rheumatology 1990 criteria.
Data including demographic characteristics, clinical,
laboratory, and radiological findings, organ involvement
status, and Birmingham vascular activity score (BVAS)
were obtained retrospectively from the patients’ medical
records. Erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), serum creatinine level, hemoglobin level,
cANCA and pANCA serology (measured with the enzymelinked immunosorbent assay method), and presence of
proteinuria and hematuria at the time of diagnosis were
all noted. Lung findings (presence of ground-glass opacity,
cavity, nodule, and/or bronchiectasis) obtained by chest
X-rays and thoracic computed tomography were also
noted. The immunosuppressants (cyclophosphamide
(CYC), rituximab (RTX), azathioprine (AZA),
methotrexate (MTX), mycophenolate mofetil (MMF), and
prednisolone) administered for the remission induction
and maintenance therapies, the duration of treatment,
and the information concerning plasmapheresis were
noted. Additionally, complications such as life-threatening
infections and the development of end-stage renal disease
that required dialysis were recorded. Data on remissions,
relapses, and mortality for all patients were also collected.
2.2. Clinical procedure
CYC and corticosteroid were administered in the remission
induction therapy. CYC (500 mg) was administered
intermittently (every 10 days during the 1st month, every 2
weeks during the next 2 months, and then every 6–8 weeks
depending on the disease activity) and intravenously.
Prednisolone was administered intravenously at 500
mg/day for 3–5 days depending on the disease activity.
For the maintenance therapy, peroral prednisolone was
administered at 1 mg/kg/day. The prednisolone dose was
tapered such that the 10–15 mg/day dose was achieved
within 3 months. All patients received the same dose
of prednisolone at the beginning of the treatment; in
addition, patients received a similar reduction regimen.
After 2011 (upon receiving the approval from the Turkish
Ministry of Health), RTX was administered twice with
a 2-week interval at a total dose of 2 g (repeated every 6
months) for the GPA patients who relapsed or who had a
refractory disease. RTX alone was not used in the remission
induction therapy. Patients with severe kidney damage
and/or alveolar hemorrhages underwent 5–7 cycles of
plasmapheresis. For the maintenance therapy, AZA (at a
dose of 2 mg/kg/day during the first 12 months, 1.5 mg/kg/
day between months 12–18, and 1 mg/kg/day after month
18), MTX (at a dose of 15–20 mg/week), MMF (2 g/day),
or RTX were administered.
For the treatment of relapse, the dose of the currently
administered corticosteroid in the maintenance therapy
was increased, the frequency of intravenous CYC
administration was increased, or RTX was administered.
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All patients who were administered with CYC and RTX
also received per oral trimethoprim/sulfamethoxazole
(800/160 mg) 3 days a week for 6 months for Pneumocystis
jirovecii prophylaxis during the induction.
2.3. Statistical analysis
The SPSS 25.0 software package (IBM Corp., Armonk,
NY, USA) was used in the statistical analysis of the data.
Categorical measurements were expressed in numbers
and percentages and continuous measurements were
expressed in mean and standard deviation (median and
minimum-maximum, where necessary) values. The chisquare test or Fisher’s test was used in the comparison
of categorical variables. Distributions were analyzed for
a comparison of continuous measurements between the
groups, wherein the Student’s t-test was used for variables
with a parametric distribution and the Mann–Whitney
U test for variables with a nonparametric distribution.
Survival curves for relapse and mortality were created
using the Kaplan–Meier analysis. A value of p < 0.05 was
considered statistically significant in all tests.
3. Results
3.1. Patients’ profile
This study involved 50 patients whose mean age was 52.8
±15.8 years, and 58% of them were female. The mean
follow-up period was 47 (3–180) months. Of the patients,
68% and 26% tested positive for cANCA and pANCA,
respectively. Diagnoses were confirmed with tissue biopsies
in 76% of the patients. The patients’ baseline demographic,
clinical, and laboratory data are shown in Table 1.
3.2. Baseline clinical results
Nearly all (92%) patients presented with symptoms, such
as fatigue, weight loss, and fever. Involvement was most
frequently observed in the lungs (86%), kidneys (72%),
and upper respiratory tract (70%). Moreover, 44% of
the patients (n = 22) had both renal and pulmonary
involvement (Table 1).
The remission rate was 80%, and the rate of refractory
disease was 20%. Additionally, 12% of the patients
exhibited full remission, and immunosuppressive therapy
was discontinued in these patients. Relapse was observed
in 46% of the GPA patients. The remission rates on the
6th, 12th, and 15th month were 16% (8 patients), 52% (26
patients), and 76% (38 patients), respectively.
For the induction therapy, in addition to the intravenous
steroid therapy, CYC alone was administered in 62% of the
patients and both CYC and RTX were administered in 36%
of the patients. For the maintenance therapy, the patients
were administered with AZA (66%), RTX (46%), MTX
(22%), and MMF (2%). The median treatment duration
was 36 (min 0, max 120) months for corticosteroids
and 24 (min 1, max 48) months for AZA. The doses for

AYDIN TUFAN et al. / Turk J Med Sci
Table 1. Patients’ baseline demographic, laboratory and clinical data.
Parameters

Values

Sex (female)*

29 (58)

Age (years)**

52.8 ± 15.8

Follow-up duration (months)***

47 (3–180)

Survival (months)**

139.2 ± 11.9

Laboratory data
ESR, mm/h**

74.6 ± 27.7

C-Reactive protein, mg/dL***

93 (9–220)

Creatinine, mg/dL***

1.3 (0.5–13.8)

Hemoglobin, g/dL**

10.6 ± 1.9

Proteinuria, g/day***

1.5 (0–9)

PR3-ANCA positivity*

34 (68)

MPO-ANCA positivity*

13 (26)

BVAS score**

20.2 ± 6.4

Clinical data
Constitutional symptoms*

46 (92)

Upper respiratory tract involvement*

35 (70)

Ear involvement*

16 (32)

Lung involvement*
1. Ground glass opacities*
2. Nodular lesions*
3. Alveolar hemorrhage*
4. Cavitary lesions*
5. Bronchiectasis*

43 (86)
25 (50)
27 (54)
19 (38)
18 (36)
6 (12)

Kidney involvement*
1. Proteinuria*
2. Hematuria*
3. Proteinuria and hematuria*
4. Renal failure*

36 (72)
34 (68)
33 (66)
32 (64)
14 (28)

Eye involvement*

6 (12)

Musculoskeletal system involvement*

23 (46)

Skin involvement*

5 (10)

Nervous system involvement*

5 (10)

Gastrointestinal tract involvement*

5 (10)

Cardiovascular system involvement*

1 (2)

Lung and kidney involvement*

22 (44)

3.3. Clinical results related to relapse
The relapse rate was higher in patients with cavitary lung
lesions than in those without cavitary lung lesions (52.2%
vs. 22.2%, p = 0.04). The relapse rate was also higher in
patients with high creatine levels than in patients with
low creatine levels (1.8 vs. 0.9, p = 0.00). The mortality
rates were 30.4% and 7.7% in patients with and without
a history of relapse, respectively (P = 0.06) (Table 2). A
multivariate logistic regression analysis was performed for
variables that were significant in the univariate analyses.
However, an independent risk factor affecting relapse was
not detected.
Age, sex, hemoglobin, sedimentation, CRP, ANCA
serology, BVAS, and duration of steroid therapy were
not found to be risk factors for relapse. Similarly, skin,
kidney (hematuria and proteinuria), lung (ground-glass
infiltration, alveolar hemorrhage, pulmonary nodules,
and bronchiectasis), upper respiratory tract (otitis and
sinusitis), musculoskeletal system, eye, heart, GI tract, and
neurological system involvement were not determined as
risk factors for relapse (Table 2).
3.4. Induction therapy
The combined use of RTX and CYC in remission induction
therapy was applied in 36% of the patients (n = 18). Of
these patients, 77.7% (n = 14) achieved remission and
22.3% (n = 4) suffered a relapse (p = 0.025)
In the remission induction therapy, the monotherapy
involving CYC was applied in 62% of the patients (n = 31).
Of these patients, 38.7% (n = 12) achieved remission and
61.3% (n = 19) suffered a relapse (p = 0.001).
The frequency of relapse was found to be significantly
lower in patients who received the combination therapy
than in patients who received the monotherapy (p = 0.003).

*n (%), **mean ± SD, ***median (min–max).

3.5. Maintenance therapy
In the maintenance therapy, no difference in terms of
relapse was observed between patients who received
RTX and those who received AZA (60.8% vs. 80%, p =
0.520), between patients who received RTX and those who
received MTX (60.8% vs. 34.8%, p = 0.769), and between
patients who received AZA and those who received MTX
(80% vs. 4.8%, p = 0.294). Thus, in the maintenance
therapy, no significant differences were observed among
the AZA, MTX, and RTX therapy in terms of relapse rates.

corticosteroids were tapered and discontinued in 38% of
the patients. The median total amount of CYC and RTX
administered per patient was 6 g (1.5–13.5 g) and 4 g (2–14
g), respectively.
In total, 12 GPA patients (24%), including 3 patients
with renal involvement and 9 patients with renal and
pulmonary involvement, underwent plasmapheresis.

3.6. Relapse-free survival rates
The mean relapse-free survival rates of the patients at
years 1, 3, and 5 were 82%, 60%, and 50%, respectively.
The estimated mean relapse-free survival period was 77.1
± 13.3 (95% CI: 51–103) months (Table 3 and Figure).
Of the patients, 28% required hemodialysis at the
time of diagnosis, 18% required hemodialysis after
the treatment, and 26% experienced a life-threatening
infection.
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Table 2. Comparison of relapsing and non-relapsing patients.
Relapsing group
(n = 23)

Nonrelapsing group
(n = 27)

p

Age (years)**

54.4 ± 15.2

51.4 ± 16.4

0.59

Sex (female)*

11 (47.8)

18 (66.7)

0.25

Renal involvement*

18 (78.3)

18 (66.7)

0.52

Lung involvement*
Ground glass opacities*
Nodular lesions*
Alveolar hemorrhage*
Cavitary lesions*
Bronchiectasis*

20 (87)
12 (52.2)
12 (52.2)
10 (43.5)
12 (52.2)
3 (13.0)

23 (85.2)
13 (48.1)
15 (55.6)
9 (33.3)
6 (22.2)
3 (11.1)

1.00
1.00
1.00
0.56
0.04
1.00

Ears involvement*

4 (17.4)

12 (44.4)

0.06

Upper respiratory tract*

18 (63.0)

17 (63.0)

0.35

Eye involvement*

4 (17.4)

12 (44.4)

0.06

Musculoskeletal involvement*

11(47.8)

12 (44.4)

1.00

Skin involvement*

1 (4.3)

4 (14.8)

0.35

PR3-ANCA positivity*

14 (60.9)

20 (74.1)

0.37

MPO-ANCA positivity*

8 (34.8)

5 (18.5)

0.21

Dialysis, at the time of diagnosis*

9 (39.1)

5 (18.5)

0.12

Serious infection*

9 (39.1)

4 (14.8)

0.06

Mortality*

7 (30.4)

2 (7.7)

0.06

Corticosteroids duration (months)**

60 ± 42

38 ± 30

0.06

ESR, mm/h**

77 ± 29

72 ± 26

0.55

CRP, mg/dL**

103 ± 72

88 ± 55

0.51

Serum creatinine, mg/dL***

1.8 (0.7–13)

0.9 (0.5–9.3)

0.00

Hematuria*

18 (78.3)

15 (55.6)

0.13

Proteinuria, g/day***

1.7 (0.0–9.0)

1.1 (0.0–5.0)

0.22

BVAS**

21.6 ± 6.8

18.9 ± 5.8

0.08

*n (%), **mean ± SD, ***median (min–max), p < 0.05 significant.
Table 3. Relapse-free survival rates of patients with GPA.

Relapse-free survival
(months)

95% confidence interval

Estimate
meana

Std. error

Lower
bound

Upper
bound

77.1

13.3

51.0

103.1

4. Discussion
4.1. Risk factors influencing the relapse rate in GPA
This study investigated the relapse rates and the risk factors
affecting relapse in 50 patients who were diagnosed with
GPA and treated in a single center. Although a marked
improvement was achieved in terms of mortality and
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1-year
survivor %

3-year
survivor %

5-year
survivor %

9-year
survivor %

82.6

60.7

50

25

progression to end-stage renal disease in GPA patients in
the preceding years, the GPA relapse rates remain high [4].
The clinical and demographic data of our patients were
similar to those reported in previous studies [6,7]. However,
the lung involvement rate was higher in our patients than
that reported in the literature (86% vs. 62%–67%) [6,7].
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Figure. Kaplan–Meier curve of relapse-free survival (months).

Similarly, the rate of pulmonary–renal involvement was
higher in our study than in previous reports (44% vs.
14.7%) [6]. This finding indicates that the present cohort
experienced more major organ involvements, such as the
lung and the kidney. The refractory disease rate (20% vs.
23%) and relapse rate (46% vs. 42%) in our study were
similar to those reported by Hogan et al. [8]. Moreover,
the reported 5-year overall relapse rate in GPA patients
was 50% [5,9,10], and a similar rate (50%) was found in
our study.
Pagnoux et al. found that lung involvement is a
predictor of relapse [4]. Another study also reported
that lung involvement was a risk factor for relapses [8].
By contrast, our study found that lung involvement is
not a risk factor for relapse. We investigated the lung
involvement subtypes, namely, bronchiectasis, and solid
nodules, and we found that they are not risk factors for
relapse. By contrast, Lhote et al. [11] reported that relapses
were more common in patients with bronchiectasis in
ANCA-associated vasculitis.
Whether the presence of cavitary lung lesions at the
time of GPA diagnosis is a risk factor is controversial.
In our study, the patients with cavitary lung lesions had
higher relapse rates than those without cavitary lung
lesions (52.2% vs. 22.2%, P = 0.04). Russell et al. [12] also
reported that relapse was more common among patients

who had cavitary lung lesions. By contrast, Komocsi et
al. reported that the presence of cavitary lesions and solid
nodules in the lungs are not risk factors for GPA relapse
[13].
The upper respiratory tract involvement is also a
risk factor for relapses in GPA as reported by Hogan et
al. [8]. However, we found that upper respiratory tract
involvement was not a risk factor for relapse.
The rate of relapse involving the same organ as that
involved at the time of diagnosis was reported to be 70.9%
[14], whereas in our study, the rate was 78.2%. The rate of
relapse involving a new organ (de novo) was reported to
be 46% [7], whereas it was found to be as low as 21.8% in
our patient series.
A review of four clinical trials reported that
cardiovascular involvement is a risk factor for relapse [15].
Unfortunately, this finding could not be verified given that
only one patient in our study had cardiac involvement.
Furthermore, low serum creatinine levels at the time
of diagnosis were reported to be associated with increased
risk of relapse rates in GPA patients [3,7,15,16] wherein
the serum creatinine cut-off value was 1.13 mg/dL (100
mmol/L) or 2.26 mg/dL (200 mmol/L). We also observed
an increased risk of relapse in patients with elevated
creatinine levels. Creatinine was associated with relapses
at a cut-off value of 1.15 mg/dL with 78.3% sensitivity, 60%
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specificity, and 69.9% accuracy (95% CI: 0.55–0.84). This
finding, however, differed from previous findings due to
the following reasons: (1) our patient group consisted only
of patients with active GPA and (2) immunosuppressants
were preferred at a lower cumulative dose in patients with
renal involvement in our study to avoid the increased risk
of drug toxicity and secondary infections.
The presence of persistent hematuria has been reported
to increase the risk of relapse [17], contrary to our findings
where hematuria is not a risk factor for relapse.
Roderau et al. [7] reported that relapse frequency was
lower in patients with skin involvement. In another study,
the presence of cutaneous ischemia, which indicates skin
involvement, has been shown to increase the risk of relapse
[18]. By contrast, only five of our patients displayed skin
involvement, indicating that skin involvement is not a risk
factor for relapse.
Some studies reported that a positive ANCA test is a
risk factor for relapse, but this report is contrary to our
findings [3]. Tomasson et al. [19] suggested that ANCA
titers should be monitored in GPA patients who are in
remission because a persistent ANCA titer positivity or
a new positivity during the follow-up could indicate a
possible future relapse. In the current study, all patients
who stopped receiving treatment due to full remission
remained ANCA negative. We conclude that the changes
in ANCA test results during follow-up should be carefully
monitored, and this approach could offer guidance in
reducing the dose of immunosuppressive agents.
4.2. Effects of different immunosuppressive regimens on
relapse in GPA
4.2.1. Remission induction
CYC and corticosteroid therapies are the cornerstone of
remission induction in the treatment of ANCA-associated
vasculitis [20]. In recent years, RTX was shown to be as
effective as CYC in both induction and maintenance
therapies [20]. The rate of CYC and corticosteroid usage in
remission induction is 74%–78% [6,21]. In our study, CYC
and corticosteroid were used in 98% of the patients for the
remission induction therapy. The higher rate of CYC and
corticosteroid usage in our series is attributed to the high
number of patients with vital organ involvement.
The rate of RTX usage in remission induction therapy
was 7.1% as reported in the Polvas registry [21]. In
another study, the rate of RTX usage in induction was
5.8% in patients in whom CYC use was ineffective [6].
In the current study, the rate of use of the RTX + CYC
combination in remission induction therapy was 36%.
In the RITUXVAS study and in our study, the
GPA patients were administered with the RTX + CYC
combination therapy for remission induction [22]. In the
RITUXVAS study, no significant differences in terms of
remission, relapse, and mortality were observed between
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the groups that were separately administered with CYC
and CYC + RTX [22].
In the current study, relapse was less common in
the group that was administered with pulse CYC+RTX
for remission induction than in the group that was
administered with CYC alone (22.3% vs. 61.3%, P = 0.003).
In our opinion, this data is important. Further prospective
clinical studies involving larger patient populations should
be conducted in order to determine the effects of RTX use
for induction on the frequency of a relapse.
A multicenter study [20] compared the use of RTX and
CYC in remission induction therapy. The remission rate
was 67% in the RTX group and 42% in the CYC group.
RTX was found to be as effective as CYC in cases involving
major kidney disease and alveolar hemorrhage [20].
The mean total dose of CYC administered in previous
studies was 7.9–14 g [21,23], whereas that in our study was
lower. As for RTX, the mean total dose administered in
previous studies was 2–8 g [21,23], which is similar to that
used in our study.
Cortazar’s study showed that combination therapy with
rituximab and cyclophosphamide is highly efficacious,
allows for rapid tapering of high-dose glucocorticoids
[24]. Pepper et al. suggested that rapid withdrawal of
corticosteroids within 2 weeks is feasible with the RTX/
CYC combined remission induction regimen [25].
Similarly, in our study, the median total amount of CYC
administered per patient was 6 g (1.5–13.5 g). Moreover,
RTX was not added to the treatment regimen until the
dose of methylprednisolone had been tapered to 32 mg/
day to avoid infections. None of the patients developed
any severe infections, hypogammaglobulinemia, or
leukopenia, and any side effects that required treatment
discontinuation were observed in this regimen.
The combined use of CYC and RTX can enables the
administration of lower cumulative doses of CYC. As a
result, we concluded that the combined therapy is necessary
to minimize the risks such as secondary malignancy and
infertility.
4.2.2. Maintenance therapy
Joode et al. [26] found that the use of AZA within less
than 12 months of maintenance therapy was associated
with increased risk of relapse. In our study, the duration
of AZA treatment was 24 months in patients with and
without relapse. Thus, AZA use was not found to be a risk
factor for relapse.
In the WEGENT trial that compared MTX and AZA,
similar relapse rates were obtained (54% vs. 60%) [27].
Our study also found no difference between AZA and
MTX in terms of relapse rates.
In the MAINRITSAN trial that compared RTX and
AZA in a maintenance therapy, the relapse rates were
lower in the RTX group [28]. By contrast, our study found
no difference between RTX and AZA in terms of relapses.
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Besada et al. [23] reported that the use of RTX in
maintenance therapy led to a lower rate of relapse;
however, treatment cessation was needed in one-third
of the patients due to infections. In our series, only two
patients stopped the RTX use due to side effects during
the maintenance therapy. RTX was discontinued because
of hepatitis B activation.
Furthermore, Roderau et al. [7] found that mortality
rates were higher in the group that suffered relapses
(19% vs. 2%, P = 0.0084). Our study similarly found that
mortality rates were higher in the group that had relapses
(30% vs. 7.7%, P = 0.06). The overall mortality rate in our
study was 18%. Although the survival period was longer
in patients who did not suffer relapses, the difference was
not significant. As regards relapse and survival, Roderau et
al. [7] reported that survival was shorter in the group with
relapses, but the difference was not significant, consistent
with our results.
Although relapses are common in the clinical course of
GPA, survival rates have been gradually improving, which
may have stemmed from the new treatment regimens,
from closer follow-ups of patients, and from earlier
detection of relapses.
Our study has a limitation, which is that it was a singlecenter, retrospective study involving a limited number of
patients. Prospective multicenter studies are warranted
to identify the risk factors affecting recurrence rates in
GPA patients. However, one strength of our study is that
it involved a homogeneous patient population consisting

of GPA patients only. Another strength is that the patients
were regularly followed-up by the same physician.
Moreover, our study had longer follow-up period than the
other studies.
5. Conclusion
Determining the correlation between the clinical signs
at the time of diagnosis and relapses in GPA patients
is important in order to determine the prognosis and
mortality risks of these patients. Our study showed
that patients with cavitary lung lesions and high serum
creatinine levels (>1.15 mg/dL) display an increased risk
for relapse. We conclude that patients with these risk
factors should be monitored carefully and closely for
relapse. In patients with severe organ involvement in GPA,
the combined use of CYC and RTX may reduce relapse,
mortality, and morbidity rates.
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